Nasdaq · CIK 0001788028
JSPR Jasper Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Sep 24, 2025. Close $0.57 on Oct 9, 2026, +67% from the 52-week low and -78% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
JSPROct 9, 2026 · close 0.57
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Jasper Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Judith Anne Shizuru director buy | $100k 41,000 shares | +35% | +9% from low-90% from high | |
| 78Notable | Ron Martell President and CEO buy | $100k 41,000 shares | +124% | +9% from low-90% from high | |
| 63Notable | Svetlana Lucas director buy | $49k 20,000 shares | - | +9% from low-90% from high | |
| 66Notable | Thomas G Wiggans director buy | $100k 41,000 shares | - | +9% from low-90% from high | |
| 0Weak | Jeetinder Singh Mahal Chief Operating Officer sell | $20k 900 shares | -3% | - |
Transactions
The last 26 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2025 | Ron Martell President and CEO | POpen-market purchase Voting Common Stock | +41,000 | $2.43 | $100k | 74,118 | Sep 24, 2025 |
| Sep 22, 2025 | Svetlana Lucas director | POpen-market purchase Voting Common Stock | +20,000 | $2.43 | $49k | 20,000 | Sep 24, 2025 |
| Sep 22, 2025 | Thomas G Wiggans director | POpen-market purchase Voting Common Stockindirect: By Wiggans Living Trust | +41,000 | $2.43 | $100k | 41,000 | Sep 24, 2025 |
| Sep 22, 2025 | Judith Anne Shizuru director | POpen-market purchase Voting Common Stock | +41,000 | $2.43 | $100k | 156,901 | Sep 24, 2025 |
| Sep 22, 2025 | Judith Anne Shizuru director | POpen-market purchase Common Stock Warrant (right to buy)derivative | +41,000 | - | - | 41,000 | Sep 24, 2025 |
| Sep 22, 2025 | Ron Martell President and CEO | POpen-market purchase Common Stock Warrant (right to buy)derivative | +41,000 | - | - | 41,000 | Sep 24, 2025 |
| Sep 22, 2025 | Svetlana Lucas director | POpen-market purchase Common Stock Warrant (right to buy)derivative | +20,000 | - | - | 20,000 | Sep 24, 2025 |
| Sep 22, 2025 | Thomas G Wiggans director | POpen-market purchase Common Stock Warrant (right to buy)derivativeindirect: By Wiggans Living Trust | +41,000 | - | - | 41,000 | Sep 24, 2025 |
| Jul 3, 2025 | Chris Nolet director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Judith Anne Shizuru director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Vishal Kapoor director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Thomas G Wiggans director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Svetlana Lucas director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Kurt Von Emster director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jul 3, 2025 | Scott C. Brun director | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jun 4, 2025 | Herb Cross Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jun 6, 2025 |
| Jun 4, 2025 | Edwin Jonathan Tucker Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jun 6, 2025 |
| Jun 4, 2025 | Jeetinder Singh Mahal Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jun 6, 2025 |
| Jun 4, 2025 | Ron Martell President and CEO | AGrant or award Stock Option (right to buy)derivative | +234,000 | $0.00 | $0 | 234,000 | Jun 6, 2025 |
| Feb 13, 2025 | Herb Cross Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Feb 18, 2025 |
| Feb 13, 2025 | Edwin Jonathan Tucker Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Feb 18, 2025 |
| Feb 13, 2025 | Ron Martell President, CEO and Director | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 18, 2025 |
| Feb 13, 2025 | Jeetinder Singh Mahal Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Feb 18, 2025 |
| Dec 12, 2024 | Jeetinder Singh Mahal Chief Operating Officer | MOption exercise Voting Common Stock10b5-1 | +900 | $7.10 | $6,390 | 25,909 | Dec 12, 2024 |
| Dec 12, 2024 | Jeetinder Singh Mahal Chief Operating Officer | SOpen-market sale Voting Common Stock10b5-1 | -900 | $22.11 | $20k | 25,009 | Dec 12, 2024 |
| Dec 12, 2024 | Jeetinder Singh Mahal Chief Operating Officer | MOption exercise Stock Option (right to buy)derivative10b5-1 | +900 | $0.00 | $0 | 13,772 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Scott C. Brundirector
- Herb CrossChief Financial Officer
- Kurt Von Emsterdirector
- Vishal Kapoordirector
- Svetlana Lucasdirector
- Ron MartellPresident and CEO
- Jeetinder Singh MahalChief Operating Officer
- Chris Noletdirector
- Judith Anne Shizurudirector
- Edwin Jonathan TuckerChief Medical Officer
- Thomas G Wiggansdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.